(2S)-N,N-dibenzyl-2-aminobutan-1-ol | 249922-60-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-N,N-dibenzyl-2-aminobutan-1-ol
• 英文别名: (S)-2-(N,N-dibenzylamino)butanol；(S)-2-(dibenzylamino)butan-1-ol；(2S)-2-(dibenzylamino)butan-1-ol
• CAS: 249922-60-9
• 化学式: C₁₈H₂₃NO
• 分子量: 269.387
• InChiKey: RWDGCGHIPSWDTF-SFHVURJKSA-N

物化性质

• 沸点：
  388.4±22.0 °C(Predicted)
• 密度：
  1.060±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2S)-N,N-dibenzyl-2-aminobutan-1-ol 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 正己烷 、 二氯甲烷 、 甲苯 为溶剂， 生成 N,N-dibenzyl-4-aminohexan-3-ol
  参考文献：
  名称：

  4,5-Dialkylsubstituted 2-imino-1,3-thiazolidine derivatives as potent inducible nitric oxide synthase inhibitors

  摘要：

  In the course of our search for selective iNOS inhibitors, we have previously reported that 2-imino-1,3-oxazolidine derivatives (1) and 2-aminothiazole derivatives (2) are selective iNOS inhibitors. In order to find more potent iNOS inhibitors, we focused our efforts on the synthesis and evaluation of the inhibitory activity against iNOS and selectivity for iNOS both in vitro and in vivo of a series of 2-imino-1,3-thiazolidine derivatives (3), which are analogues of I and 2. Our results show that among the compounds synthesized (4R,5R)-5-ethyl-2-imino-4-methyl-1,3-thiazolidine [(4R,5R)-14a: ES-1537] exhibited potent inhibitory activity and selectivity for iNOS. In addition, ES-1537 had good pharmacokinetic profile in rats with BA value of 80%. It is therefore expected that ES-1537 may be therapeutically useful for the treatment of diseases related to excess production of NO. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.031
• 作为产物：
  描述：

  (R)-O-(2-bisphenylmethylamino)butyrylpantolactone 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 16.5h， 生成 (2S)-N,N-dibenzyl-2-aminobutan-1-ol
  参考文献：
  名称：

  Enantioselective Synthesis of β-Dibenzylamino Alcohols via a Dynamic Kinetic Resolution of α-Halo Acids

  摘要：

  DOI：

  10.1021/jo9712714

文献信息

• Palladium-N-Heterocyclic Carbene (NHC)-Catalyzed Asymmetric Synthesis of Indolines through Regiodivergent C(sp³)H Activation: Scope and DFT Study
  作者：Dmitry Katayev、Evgeny Larionov、Masafumi Nakanishi、Céline Besnard、E. Peter Kündig

  DOI：10.1002/chem.201403985

  日期：2014.11.10

  Two bulky, chiral, monodentate N‐heterocyclic carbene ligands were applied to palladium‐catalyzed asymmetric CH arylation to incorporate C(sp3)H bond activation. Racemic mixtures of the carbamate starting materials underwent regiodivergent reactions to afford different trans‐2,3‐substituted indolines. Although this CArCalkyl coupling requires high temperatures (140–160 °C), chiral induction is high

  将两个庞大的手性单齿N杂环卡宾配体应用于钯催化的不对称CH芳基化反应，以结合C（sp 3）H键活化作用。氨基甲酸酯原料的外消旋混合物进行区域扩散反应，得到不同的反式-2,3-取代的二氢吲哚。虽然本C的Ar  Ç烷基耦合需要高温（140-160℃），手性诱导高。当与对映体纯原料一起进行时，该区域发散反应可导致单一结构上不同的对映体纯产物，这取决于催化剂的手性。的C 仅在环丙基的情况下，才能在叔中心实现H活化。没有CH激活发生在第三级中心的α处。详细的研究DFT被包括和的分析甲基与亚甲基相对于次甲基Ç  ħ活化用于合理化实验观察到的区域选择性和对映选择性。
• COMPOUNDS
  申请人：SHELDRAKE Peter William

  公开号：US20100093769A1

  公开（公告）日：2010-04-15

  The present invention relates to compounds of formula (I) wherein: R 1 and R 2 are each independently H, alkyl or haloalkyl; R 3 and R 4 are each independently H, alkyl, haloalkyl or aryl; R 5 is alkyl or cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R 6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and where one of X, Y and Z is N and the remainder are CR 9 ; R 7 , R 8 and each R 9 are independently H, alkyl or haloalkyl, wherein at least one of R 7 , R 8 and each R 9 is other than H. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula (I), and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及式(I)化合物，其中： R1和R2各自独立地为H、烷基或卤代烷基； R3和R4各自独立地为H、烷基、卤代烷基或芳基； R5为烷基或环烷基或环烷基烷基，每个基团可以选择性地被一个或多个OH基团取代； R6选自环丙基氨基、环丙基甲基氨基、环丁基氨基、环丁基甲基氨基和其中的一个，其中X、Y和Z中的一个为N，其余为CR9； R7、R8和每个R9各自独立地为H、烷基或卤代烷基，其中至少一个R7、R8和每个R9不是H。 本发明的另一个方面涉及包含式(I)化合物的药物组合物，以及使用该化合物治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病的方法。
• COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS
  申请人：GREEN Simon

  公开号：US20100143350A1

  公开（公告）日：2010-06-10

  The present invention relates to combination comprising (i) an ErbB inhibitor; and (ii) a CDK inhibitor, or a pharmaceutically acceptable salt thereof, selected from: (a) roscovitine; (b) 3-9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-pentan-2-ol; (c) 3-9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-pentan-2-ol; and (d) (2R,3S-3-(6-((4,6-dimethylpyridin-3-ylmethylamino)-9-isopropyl-9H-purin-2-ylamino)pentan-2-ol. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising combinations according to the invention, and methods of treatment using the same.

  本发明涉及一种组合物，包括（i）ErbB抑制剂；和（ii）CDK抑制剂，或其药学上可接受的盐，所选自：（a）罗斯可维汀；（b）3-9-异丙基-6-[(吡啶-3-基甲基)-氨基]-9H-嘌呤-2-基氨基}-2-甲基戊烷-2-醇；（c）3-9-异丙基-6-[(吡啶-3-基甲基)-氨基]-9H-嘌呤-2-基氨基}-戊烷-2-醇；和（d）（2R,3S-3-(6-((4,6-二甲基吡啶-3-基甲基氨基)-9-异丙基-9H-嘌呤-2-基氨基)戊烷-2-醇。本发明的其他方面涉及包括本发明的组合物的制药产品和制药组合物，以及使用它们进行治疗的方法。
• Trisubstituted purine derivatives
  申请人：Sheldrake Peter William

  公开号：US08592581B2

  公开（公告）日：2013-11-26

  The present invention relates to compounds of formula (I) wherein: R1 and R2 are each independently H, alkyl or haloalkyl; R3 and R4 are each independently H, alkyl, haloalkyl or aryl; R5 is alkyl or cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and where one of X, Y and Z is N and the remainder are CR9; R7, R8 and each R9 are independently H, alkyl or haloalkyl, wherein at least one of R7, R8 and each R9 is other than H. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula (I), and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及式（I）的化合物，其中： R1和R2各自独立地为H、烷基或卤代烷基； R3和R4各自独立地为H、烷基、卤代烷基或芳基； R5为烷基或环烷基或环烷基烷基，其中每个基团可以选择地被一个或多个OH基团取代； R6选择自环丙氨基、环丙甲基氨基、环丁氨基、环丁甲基氨基和其中X、Y和Z中的一个为N，其余为CR9； R7、R8和每个R9各自独立地为H、烷基或卤代烷基，其中至少一个R7、R8和每个R9不是H。 本发明的另一个方面涉及包含式（I）的化合物的制药组合物，以及使用该化合物治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病的用途。
• Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders
  申请人：Green Simon

  公开号：US09173938B2

  公开（公告）日：2015-11-03

  The present invention relates to combination comprising (i) an ErbB inhibitor; and (ii) a CDK inhibitor, or a pharmaceutically acceptable salt thereof, selected from: (a) roscovitine; (b) 3-9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-pentan-2-ol; (c) 3-9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-pentan-2-ol; and (d) (2R,3S-3-(6-((4,6-dimethylpyridin-3-ylmethylamino)-9-isopropyl-9H-purin-2-ylamino)pentan-2-ol. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising combinations according to the invention, and methods of treatment using the same.

  本发明涉及一种组合物，包括（i）一种ErbB抑制剂；和（ii）一种CDK抑制剂，或其药学上可接受的盐，所选自：（a）罗斯可维汀；（b）3-9-异丙基-6-[(吡啶-3-基甲基)-氨基]-9H-嘌呤-2-基氨基}-2-甲基戊-2-醇；（c）3-9-异丙基-6-[(吡啶-3-基甲基)-氨基]-9H-嘌呤-2-基氨基}-戊-2-醇；和（d）（2R,3S-3-(6-((4,6-二甲基吡啶-3-基甲基氨基)-9-异丙基-9H-嘌呤-2-基氨基)戊-2-醇）。本发明的其他方面涉及按照本发明的组合物组成的制药产品和制药组合物，以及使用它们的治疗方法。